nodes	percent_of_prediction	percent_of_DWPC	metapath
Vardenafil—PDE5A—clitoris—ovarian cancer	0.111	0.467	CbGeAlD
Vardenafil—CYP3A5—Paclitaxel—ovarian cancer	0.0539	0.253	CbGbCtD
Vardenafil—CYP3A4—Topotecan—ovarian cancer	0.0424	0.2	CbGbCtD
Vardenafil—CYP3A5—Docetaxel—ovarian cancer	0.0389	0.183	CbGbCtD
Vardenafil—CYP3A4—Vinorelbine—ovarian cancer	0.0299	0.141	CbGbCtD
Vardenafil—CYP3A4—Paclitaxel—ovarian cancer	0.021	0.0988	CbGbCtD
Vardenafil—CYP3A4—Docetaxel—ovarian cancer	0.0152	0.0714	CbGbCtD
Vardenafil—PDE11A—epithelium—ovarian cancer	0.0145	0.0611	CbGeAlD
Vardenafil—CYP3A4—Doxorubicin—ovarian cancer	0.0113	0.0532	CbGbCtD
Vardenafil—PDE10A—decidua—ovarian cancer	0.00888	0.0375	CbGeAlD
Vardenafil—PDE11A—testis—ovarian cancer	0.00867	0.0366	CbGeAlD
Vardenafil—PDE6G—testis—ovarian cancer	0.00835	0.0352	CbGeAlD
Vardenafil—PDE1B—gonad—ovarian cancer	0.00775	0.0327	CbGeAlD
Vardenafil—PDE1B—female reproductive system—ovarian cancer	0.00692	0.0292	CbGeAlD
Vardenafil—PDE10A—female gonad—ovarian cancer	0.00636	0.0268	CbGeAlD
Vardenafil—PDE6G—lymph node—ovarian cancer	0.00605	0.0255	CbGeAlD
Vardenafil—PDE10A—testis—ovarian cancer	0.00564	0.0238	CbGeAlD
Vardenafil—PDE1B—testis—ovarian cancer	0.00559	0.0236	CbGeAlD
Vardenafil—PDE5A—epithelium—ovarian cancer	0.0055	0.0232	CbGeAlD
Vardenafil—PDE5A—uterine cervix—ovarian cancer	0.00546	0.023	CbGeAlD
Vardenafil—PDE5A—gonad—ovarian cancer	0.00458	0.0193	CbGeAlD
Vardenafil—PDE5A—female reproductive system—ovarian cancer	0.00409	0.0173	CbGeAlD
Vardenafil—PDE10A—lymph node—ovarian cancer	0.00409	0.0173	CbGeAlD
Vardenafil—PDE1B—lymph node—ovarian cancer	0.00405	0.0171	CbGeAlD
Vardenafil—PDE5A—female gonad—ovarian cancer	0.00372	0.0157	CbGeAlD
Vardenafil—PDE5A—vagina—ovarian cancer	0.0037	0.0156	CbGeAlD
Vardenafil—PDE5A—testis—ovarian cancer	0.0033	0.0139	CbGeAlD
Vardenafil—PDE5A—lymph node—ovarian cancer	0.00239	0.0101	CbGeAlD
Vardenafil—CYP3A5—uterine cervix—ovarian cancer	0.00227	0.00957	CbGeAlD
Vardenafil—CYP3A5—female gonad—ovarian cancer	0.00155	0.00652	CbGeAlD
Vardenafil—CYP3A5—vagina—ovarian cancer	0.00154	0.00649	CbGeAlD
Vardenafil—CYP3A4—female reproductive system—ovarian cancer	0.00127	0.00538	CbGeAlD
Vardenafil—Aspartate aminotransferase increased—Epirubicin—ovarian cancer	0.000518	0.00128	CcSEcCtD
Vardenafil—Mental disorder—Docetaxel—ovarian cancer	0.000516	0.00128	CcSEcCtD
Vardenafil—Arthralgia—Paclitaxel—ovarian cancer	0.000515	0.00128	CcSEcCtD
Vardenafil—Chest pain—Paclitaxel—ovarian cancer	0.000515	0.00128	CcSEcCtD
Vardenafil—Myalgia—Paclitaxel—ovarian cancer	0.000515	0.00128	CcSEcCtD
Vardenafil—Anxiety—Paclitaxel—ovarian cancer	0.000514	0.00127	CcSEcCtD
Vardenafil—Face oedema—Doxorubicin—ovarian cancer	0.000513	0.00127	CcSEcCtD
Vardenafil—Erythema—Docetaxel—ovarian cancer	0.000513	0.00127	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Paclitaxel—ovarian cancer	0.000512	0.00127	CcSEcCtD
Vardenafil—Nausea—Topotecan—ovarian cancer	0.00051	0.00127	CcSEcCtD
Vardenafil—Discomfort—Paclitaxel—ovarian cancer	0.000509	0.00126	CcSEcCtD
Vardenafil—Gastritis—Epirubicin—ovarian cancer	0.000509	0.00126	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Epirubicin—ovarian cancer	0.000507	0.00126	CcSEcCtD
Vardenafil—Dry mouth—Paclitaxel—ovarian cancer	0.000504	0.00125	CcSEcCtD
Vardenafil—Diarrhoea—Vinorelbine—ovarian cancer	0.000503	0.00125	CcSEcCtD
Vardenafil—Nausea—Melphalan—ovarian cancer	0.000499	0.00124	CcSEcCtD
Vardenafil—Blood creatinine increased—Doxorubicin—ovarian cancer	0.000498	0.00124	CcSEcCtD
Vardenafil—Dysphagia—Epirubicin—ovarian cancer	0.000497	0.00123	CcSEcCtD
Vardenafil—Influenza—Epirubicin—ovarian cancer	0.000497	0.00123	CcSEcCtD
Vardenafil—Back pain—Docetaxel—ovarian cancer	0.000496	0.00123	CcSEcCtD
Vardenafil—Anaphylactic shock—Paclitaxel—ovarian cancer	0.000494	0.00123	CcSEcCtD
Vardenafil—Muscle spasms—Docetaxel—ovarian cancer	0.000493	0.00122	CcSEcCtD
Vardenafil—Liver function test abnormal—Doxorubicin—ovarian cancer	0.000491	0.00122	CcSEcCtD
Vardenafil—Infection—Paclitaxel—ovarian cancer	0.000491	0.00122	CcSEcCtD
Vardenafil—Shock—Paclitaxel—ovarian cancer	0.000486	0.00121	CcSEcCtD
Vardenafil—Dizziness—Vinorelbine—ovarian cancer	0.000486	0.00121	CcSEcCtD
Vardenafil—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.000486	0.00121	CcSEcCtD
Vardenafil—Abdominal pain upper—Doxorubicin—ovarian cancer	0.000486	0.00121	CcSEcCtD
Vardenafil—Nervous system disorder—Paclitaxel—ovarian cancer	0.000485	0.0012	CcSEcCtD
Vardenafil—Angina pectoris—Epirubicin—ovarian cancer	0.000484	0.0012	CcSEcCtD
Vardenafil—Tachycardia—Paclitaxel—ovarian cancer	0.000482	0.0012	CcSEcCtD
Vardenafil—Breast disorder—Doxorubicin—ovarian cancer	0.000481	0.00119	CcSEcCtD
Vardenafil—Skin disorder—Paclitaxel—ovarian cancer	0.00048	0.00119	CcSEcCtD
Vardenafil—Aspartate aminotransferase increased—Doxorubicin—ovarian cancer	0.000479	0.00119	CcSEcCtD
Vardenafil—Hyperhidrosis—Paclitaxel—ovarian cancer	0.000478	0.00119	CcSEcCtD
Vardenafil—Gastritis—Doxorubicin—ovarian cancer	0.000471	0.00117	CcSEcCtD
Vardenafil—Alanine aminotransferase increased—Doxorubicin—ovarian cancer	0.000469	0.00116	CcSEcCtD
Vardenafil—Vomiting—Vinorelbine—ovarian cancer	0.000467	0.00116	CcSEcCtD
Vardenafil—Rash—Vinorelbine—ovarian cancer	0.000463	0.00115	CcSEcCtD
Vardenafil—Dermatitis—Vinorelbine—ovarian cancer	0.000463	0.00115	CcSEcCtD
Vardenafil—Hypotension—Paclitaxel—ovarian cancer	0.000462	0.00115	CcSEcCtD
Vardenafil—Headache—Vinorelbine—ovarian cancer	0.00046	0.00114	CcSEcCtD
Vardenafil—Syncope—Docetaxel—ovarian cancer	0.00046	0.00114	CcSEcCtD
Vardenafil—Dysphagia—Doxorubicin—ovarian cancer	0.00046	0.00114	CcSEcCtD
Vardenafil—Influenza—Doxorubicin—ovarian cancer	0.00046	0.00114	CcSEcCtD
Vardenafil—Palpitations—Docetaxel—ovarian cancer	0.000453	0.00113	CcSEcCtD
Vardenafil—Photosensitivity reaction—Epirubicin—ovarian cancer	0.000453	0.00113	CcSEcCtD
Vardenafil—Loss of consciousness—Docetaxel—ovarian cancer	0.000451	0.00112	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Paclitaxel—ovarian cancer	0.00045	0.00112	CcSEcCtD
Vardenafil—Angina pectoris—Doxorubicin—ovarian cancer	0.000448	0.00111	CcSEcCtD
Vardenafil—Insomnia—Paclitaxel—ovarian cancer	0.000447	0.00111	CcSEcCtD
Vardenafil—Convulsion—Docetaxel—ovarian cancer	0.000445	0.0011	CcSEcCtD
Vardenafil—Paraesthesia—Paclitaxel—ovarian cancer	0.000444	0.0011	CcSEcCtD
Vardenafil—Infestation—Epirubicin—ovarian cancer	0.000443	0.0011	CcSEcCtD
Vardenafil—Infestation NOS—Epirubicin—ovarian cancer	0.000443	0.0011	CcSEcCtD
Vardenafil—Dyspnoea—Paclitaxel—ovarian cancer	0.000441	0.00109	CcSEcCtD
Vardenafil—Somnolence—Paclitaxel—ovarian cancer	0.000439	0.00109	CcSEcCtD
Vardenafil—Arthralgia—Docetaxel—ovarian cancer	0.000437	0.00108	CcSEcCtD
Vardenafil—Chest pain—Docetaxel—ovarian cancer	0.000437	0.00108	CcSEcCtD
Vardenafil—Myalgia—Docetaxel—ovarian cancer	0.000437	0.00108	CcSEcCtD
Vardenafil—Nausea—Vinorelbine—ovarian cancer	0.000436	0.00108	CcSEcCtD
Vardenafil—Dyspepsia—Paclitaxel—ovarian cancer	0.000435	0.00108	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000434	0.00108	CcSEcCtD
Vardenafil—Conjunctivitis—Epirubicin—ovarian cancer	0.000431	0.00107	CcSEcCtD
Vardenafil—Dry mouth—Docetaxel—ovarian cancer	0.000427	0.00106	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000427	0.00106	CcSEcCtD
Vardenafil—Sweating—Epirubicin—ovarian cancer	0.000425	0.00105	CcSEcCtD
Vardenafil—Pain—Paclitaxel—ovarian cancer	0.000423	0.00105	CcSEcCtD
Vardenafil—Haematuria—Epirubicin—ovarian cancer	0.000422	0.00105	CcSEcCtD
Vardenafil—Photosensitivity reaction—Doxorubicin—ovarian cancer	0.00042	0.00104	CcSEcCtD
Vardenafil—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000419	0.00104	CcSEcCtD
Vardenafil—Anaphylactic shock—Docetaxel—ovarian cancer	0.000419	0.00104	CcSEcCtD
Vardenafil—Epistaxis—Epirubicin—ovarian cancer	0.000418	0.00104	CcSEcCtD
Vardenafil—Infection—Docetaxel—ovarian cancer	0.000416	0.00103	CcSEcCtD
Vardenafil—Sinusitis—Epirubicin—ovarian cancer	0.000416	0.00103	CcSEcCtD
Vardenafil—Shock—Docetaxel—ovarian cancer	0.000412	0.00102	CcSEcCtD
Vardenafil—Nervous system disorder—Docetaxel—ovarian cancer	0.000411	0.00102	CcSEcCtD
Vardenafil—Infestation NOS—Doxorubicin—ovarian cancer	0.00041	0.00102	CcSEcCtD
Vardenafil—Infestation—Doxorubicin—ovarian cancer	0.00041	0.00102	CcSEcCtD
Vardenafil—Tachycardia—Docetaxel—ovarian cancer	0.000409	0.00101	CcSEcCtD
Vardenafil—Feeling abnormal—Paclitaxel—ovarian cancer	0.000407	0.00101	CcSEcCtD
Vardenafil—Skin disorder—Docetaxel—ovarian cancer	0.000407	0.00101	CcSEcCtD
Vardenafil—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000404	0.001	CcSEcCtD
Vardenafil—Haemoglobin—Epirubicin—ovarian cancer	0.0004	0.000992	CcSEcCtD
Vardenafil—Rhinitis—Epirubicin—ovarian cancer	0.000399	0.000989	CcSEcCtD
Vardenafil—Conjunctivitis—Doxorubicin—ovarian cancer	0.000398	0.000989	CcSEcCtD
Vardenafil—Haemorrhage—Epirubicin—ovarian cancer	0.000398	0.000987	CcSEcCtD
Vardenafil—Hypoaesthesia—Epirubicin—ovarian cancer	0.000396	0.000982	CcSEcCtD
Vardenafil—Pharyngitis—Epirubicin—ovarian cancer	0.000395	0.000979	CcSEcCtD
Vardenafil—Sweating—Doxorubicin—ovarian cancer	0.000393	0.000975	CcSEcCtD
Vardenafil—Urinary tract disorder—Epirubicin—ovarian cancer	0.000393	0.000974	CcSEcCtD
Vardenafil—Hypotension—Docetaxel—ovarian cancer	0.000391	0.000971	CcSEcCtD
Vardenafil—Haematuria—Doxorubicin—ovarian cancer	0.000391	0.00097	CcSEcCtD
Vardenafil—Connective tissue disorder—Epirubicin—ovarian cancer	0.000391	0.00097	CcSEcCtD
Vardenafil—Abdominal pain—Paclitaxel—ovarian cancer	0.000391	0.000969	CcSEcCtD
Vardenafil—Urethral disorder—Epirubicin—ovarian cancer	0.00039	0.000967	CcSEcCtD
Vardenafil—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.000388	0.000962	CcSEcCtD
Vardenafil—Epistaxis—Doxorubicin—ovarian cancer	0.000387	0.000959	CcSEcCtD
Vardenafil—Sinusitis—Doxorubicin—ovarian cancer	0.000384	0.000954	CcSEcCtD
Vardenafil—Visual impairment—Epirubicin—ovarian cancer	0.000383	0.000951	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000382	0.000947	CcSEcCtD
Vardenafil—Insomnia—Docetaxel—ovarian cancer	0.000379	0.00094	CcSEcCtD
Vardenafil—Paraesthesia—Docetaxel—ovarian cancer	0.000376	0.000933	CcSEcCtD
Vardenafil—Dyspnoea—Docetaxel—ovarian cancer	0.000373	0.000927	CcSEcCtD
Vardenafil—Somnolence—Docetaxel—ovarian cancer	0.000372	0.000924	CcSEcCtD
Vardenafil—Eye disorder—Epirubicin—ovarian cancer	0.000372	0.000922	CcSEcCtD
Vardenafil—Tinnitus—Epirubicin—ovarian cancer	0.000371	0.00092	CcSEcCtD
Vardenafil—Haemoglobin—Doxorubicin—ovarian cancer	0.00037	0.000918	CcSEcCtD
Vardenafil—Flushing—Epirubicin—ovarian cancer	0.000369	0.000916	CcSEcCtD
Vardenafil—Cardiac disorder—Epirubicin—ovarian cancer	0.000369	0.000916	CcSEcCtD
Vardenafil—Rhinitis—Doxorubicin—ovarian cancer	0.000369	0.000915	CcSEcCtD
Vardenafil—Dyspepsia—Docetaxel—ovarian cancer	0.000369	0.000915	CcSEcCtD
Vardenafil—Haemorrhage—Doxorubicin—ovarian cancer	0.000368	0.000913	CcSEcCtD
Vardenafil—Hypoaesthesia—Doxorubicin—ovarian cancer	0.000366	0.000908	CcSEcCtD
Vardenafil—Pharyngitis—Doxorubicin—ovarian cancer	0.000365	0.000906	CcSEcCtD
Vardenafil—Hypersensitivity—Paclitaxel—ovarian cancer	0.000364	0.000903	CcSEcCtD
Vardenafil—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000363	0.000902	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000362	0.000897	CcSEcCtD
Vardenafil—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000362	0.000897	CcSEcCtD
Vardenafil—Angiopathy—Epirubicin—ovarian cancer	0.000361	0.000895	CcSEcCtD
Vardenafil—Urethral disorder—Doxorubicin—ovarian cancer	0.000361	0.000895	CcSEcCtD
Vardenafil—Immune system disorder—Epirubicin—ovarian cancer	0.000359	0.000891	CcSEcCtD
Vardenafil—Mediastinal disorder—Epirubicin—ovarian cancer	0.000358	0.000889	CcSEcCtD
Vardenafil—Pain—Docetaxel—ovarian cancer	0.000358	0.000889	CcSEcCtD
Vardenafil—Visual impairment—Doxorubicin—ovarian cancer	0.000355	0.00088	CcSEcCtD
Vardenafil—Asthenia—Paclitaxel—ovarian cancer	0.000355	0.00088	CcSEcCtD
Vardenafil—Pruritus—Paclitaxel—ovarian cancer	0.00035	0.000868	CcSEcCtD
Vardenafil—Mental disorder—Epirubicin—ovarian cancer	0.000348	0.000864	CcSEcCtD
Vardenafil—Erythema—Epirubicin—ovarian cancer	0.000346	0.000859	CcSEcCtD
Vardenafil—Feeling abnormal—Docetaxel—ovarian cancer	0.000345	0.000856	CcSEcCtD
Vardenafil—Eye disorder—Doxorubicin—ovarian cancer	0.000344	0.000853	CcSEcCtD
Vardenafil—Tinnitus—Doxorubicin—ovarian cancer	0.000343	0.000851	CcSEcCtD
Vardenafil—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000342	0.00085	CcSEcCtD
Vardenafil—Flushing—Doxorubicin—ovarian cancer	0.000341	0.000847	CcSEcCtD
Vardenafil—Cardiac disorder—Doxorubicin—ovarian cancer	0.000341	0.000847	CcSEcCtD
Vardenafil—Diarrhoea—Paclitaxel—ovarian cancer	0.000338	0.000839	CcSEcCtD
Vardenafil—Back pain—Epirubicin—ovarian cancer	0.000335	0.000831	CcSEcCtD
Vardenafil—Angiopathy—Doxorubicin—ovarian cancer	0.000334	0.000828	CcSEcCtD
Vardenafil—Muscle spasms—Epirubicin—ovarian cancer	0.000333	0.000826	CcSEcCtD
Vardenafil—Immune system disorder—Doxorubicin—ovarian cancer	0.000332	0.000825	CcSEcCtD
Vardenafil—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000332	0.000823	CcSEcCtD
Vardenafil—Abdominal pain—Docetaxel—ovarian cancer	0.000331	0.000822	CcSEcCtD
Vardenafil—Dizziness—Paclitaxel—ovarian cancer	0.000327	0.000811	CcSEcCtD
Vardenafil—Vision blurred—Epirubicin—ovarian cancer	0.000326	0.000809	CcSEcCtD
Vardenafil—Mental disorder—Doxorubicin—ovarian cancer	0.000322	0.0008	CcSEcCtD
Vardenafil—Ill-defined disorder—Epirubicin—ovarian cancer	0.000321	0.000797	CcSEcCtD
Vardenafil—Erythema—Doxorubicin—ovarian cancer	0.00032	0.000795	CcSEcCtD
Vardenafil—Vomiting—Paclitaxel—ovarian cancer	0.000314	0.00078	CcSEcCtD
Vardenafil—Malaise—Epirubicin—ovarian cancer	0.000312	0.000775	CcSEcCtD
Vardenafil—Rash—Paclitaxel—ovarian cancer	0.000312	0.000773	CcSEcCtD
Vardenafil—Dermatitis—Paclitaxel—ovarian cancer	0.000311	0.000772	CcSEcCtD
Vardenafil—Vertigo—Epirubicin—ovarian cancer	0.000311	0.000772	CcSEcCtD
Vardenafil—Syncope—Epirubicin—ovarian cancer	0.00031	0.00077	CcSEcCtD
Vardenafil—Back pain—Doxorubicin—ovarian cancer	0.00031	0.000769	CcSEcCtD
Vardenafil—Headache—Paclitaxel—ovarian cancer	0.00031	0.000768	CcSEcCtD
Vardenafil—Hypersensitivity—Docetaxel—ovarian cancer	0.000309	0.000766	CcSEcCtD
Vardenafil—Muscle spasms—Doxorubicin—ovarian cancer	0.000308	0.000764	CcSEcCtD
Vardenafil—Palpitations—Epirubicin—ovarian cancer	0.000306	0.000759	CcSEcCtD
Vardenafil—Loss of consciousness—Epirubicin—ovarian cancer	0.000304	0.000755	CcSEcCtD
Vardenafil—Vision blurred—Doxorubicin—ovarian cancer	0.000302	0.000749	CcSEcCtD
Vardenafil—Asthenia—Docetaxel—ovarian cancer	0.0003	0.000746	CcSEcCtD
Vardenafil—Convulsion—Epirubicin—ovarian cancer	0.0003	0.000744	CcSEcCtD
Vardenafil—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000297	0.000737	CcSEcCtD
Vardenafil—Pruritus—Docetaxel—ovarian cancer	0.000296	0.000735	CcSEcCtD
Vardenafil—Myalgia—Epirubicin—ovarian cancer	0.000295	0.000731	CcSEcCtD
Vardenafil—Chest pain—Epirubicin—ovarian cancer	0.000295	0.000731	CcSEcCtD
Vardenafil—Arthralgia—Epirubicin—ovarian cancer	0.000295	0.000731	CcSEcCtD
Vardenafil—Anxiety—Epirubicin—ovarian cancer	0.000294	0.000729	CcSEcCtD
Vardenafil—Nausea—Paclitaxel—ovarian cancer	0.000293	0.000728	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000293	0.000726	CcSEcCtD
Vardenafil—Discomfort—Epirubicin—ovarian cancer	0.000291	0.000722	CcSEcCtD
Vardenafil—Malaise—Doxorubicin—ovarian cancer	0.000289	0.000717	CcSEcCtD
Vardenafil—Dry mouth—Epirubicin—ovarian cancer	0.000288	0.000715	CcSEcCtD
Vardenafil—Vertigo—Doxorubicin—ovarian cancer	0.000288	0.000714	CcSEcCtD
Vardenafil—Syncope—Doxorubicin—ovarian cancer	0.000287	0.000713	CcSEcCtD
Vardenafil—Diarrhoea—Docetaxel—ovarian cancer	0.000287	0.000711	CcSEcCtD
Vardenafil—Palpitations—Doxorubicin—ovarian cancer	0.000283	0.000702	CcSEcCtD
Vardenafil—Anaphylactic shock—Epirubicin—ovarian cancer	0.000282	0.000701	CcSEcCtD
Vardenafil—Loss of consciousness—Doxorubicin—ovarian cancer	0.000281	0.000699	CcSEcCtD
Vardenafil—Infection—Epirubicin—ovarian cancer	0.000281	0.000696	CcSEcCtD
Vardenafil—Shock—Epirubicin—ovarian cancer	0.000278	0.00069	CcSEcCtD
Vardenafil—Convulsion—Doxorubicin—ovarian cancer	0.000277	0.000689	CcSEcCtD
Vardenafil—Nervous system disorder—Epirubicin—ovarian cancer	0.000277	0.000687	CcSEcCtD
Vardenafil—Dizziness—Docetaxel—ovarian cancer	0.000277	0.000687	CcSEcCtD
Vardenafil—Tachycardia—Epirubicin—ovarian cancer	0.000276	0.000684	CcSEcCtD
Vardenafil—Skin disorder—Epirubicin—ovarian cancer	0.000274	0.000681	CcSEcCtD
Vardenafil—Hyperhidrosis—Epirubicin—ovarian cancer	0.000273	0.000678	CcSEcCtD
Vardenafil—Arthralgia—Doxorubicin—ovarian cancer	0.000273	0.000677	CcSEcCtD
Vardenafil—Chest pain—Doxorubicin—ovarian cancer	0.000273	0.000677	CcSEcCtD
Vardenafil—Myalgia—Doxorubicin—ovarian cancer	0.000273	0.000677	CcSEcCtD
Vardenafil—Anxiety—Doxorubicin—ovarian cancer	0.000272	0.000674	CcSEcCtD
Vardenafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000271	0.000672	CcSEcCtD
Vardenafil—Discomfort—Doxorubicin—ovarian cancer	0.000269	0.000669	CcSEcCtD
Vardenafil—Dry mouth—Doxorubicin—ovarian cancer	0.000267	0.000662	CcSEcCtD
Vardenafil—Vomiting—Docetaxel—ovarian cancer	0.000266	0.000661	CcSEcCtD
Vardenafil—Rash—Docetaxel—ovarian cancer	0.000264	0.000655	CcSEcCtD
Vardenafil—Hypotension—Epirubicin—ovarian cancer	0.000264	0.000655	CcSEcCtD
Vardenafil—Dermatitis—Docetaxel—ovarian cancer	0.000264	0.000655	CcSEcCtD
Vardenafil—Headache—Docetaxel—ovarian cancer	0.000262	0.000651	CcSEcCtD
Vardenafil—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000261	0.000649	CcSEcCtD
Vardenafil—Infection—Doxorubicin—ovarian cancer	0.00026	0.000644	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000257	0.000639	CcSEcCtD
Vardenafil—Shock—Doxorubicin—ovarian cancer	0.000257	0.000638	CcSEcCtD
Vardenafil—Nervous system disorder—Doxorubicin—ovarian cancer	0.000256	0.000636	CcSEcCtD
Vardenafil—Insomnia—Epirubicin—ovarian cancer	0.000255	0.000634	CcSEcCtD
Vardenafil—Tachycardia—Doxorubicin—ovarian cancer	0.000255	0.000633	CcSEcCtD
Vardenafil—Skin disorder—Doxorubicin—ovarian cancer	0.000254	0.00063	CcSEcCtD
Vardenafil—Paraesthesia—Epirubicin—ovarian cancer	0.000254	0.000629	CcSEcCtD
Vardenafil—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000253	0.000627	CcSEcCtD
Vardenafil—Dyspnoea—Epirubicin—ovarian cancer	0.000252	0.000625	CcSEcCtD
Vardenafil—Somnolence—Epirubicin—ovarian cancer	0.000251	0.000623	CcSEcCtD
Vardenafil—Nausea—Docetaxel—ovarian cancer	0.000249	0.000617	CcSEcCtD
Vardenafil—Dyspepsia—Epirubicin—ovarian cancer	0.000249	0.000617	CcSEcCtD
Vardenafil—Hypotension—Doxorubicin—ovarian cancer	0.000244	0.000606	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000244	0.000605	CcSEcCtD
Vardenafil—Pain—Epirubicin—ovarian cancer	0.000242	0.000599	CcSEcCtD
Vardenafil—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000238	0.000591	CcSEcCtD
Vardenafil—Insomnia—Doxorubicin—ovarian cancer	0.000236	0.000587	CcSEcCtD
Vardenafil—Paraesthesia—Doxorubicin—ovarian cancer	0.000235	0.000582	CcSEcCtD
Vardenafil—Dyspnoea—Doxorubicin—ovarian cancer	0.000233	0.000578	CcSEcCtD
Vardenafil—Feeling abnormal—Epirubicin—ovarian cancer	0.000233	0.000578	CcSEcCtD
Vardenafil—Somnolence—Doxorubicin—ovarian cancer	0.000232	0.000577	CcSEcCtD
Vardenafil—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000231	0.000573	CcSEcCtD
Vardenafil—Dyspepsia—Doxorubicin—ovarian cancer	0.00023	0.000571	CcSEcCtD
Vardenafil—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000226	0.00056	CcSEcCtD
Vardenafil—Pain—Doxorubicin—ovarian cancer	0.000224	0.000555	CcSEcCtD
Vardenafil—Abdominal pain—Epirubicin—ovarian cancer	0.000223	0.000554	CcSEcCtD
Vardenafil—Feeling abnormal—Doxorubicin—ovarian cancer	0.000215	0.000535	CcSEcCtD
Vardenafil—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000214	0.00053	CcSEcCtD
Vardenafil—Hypersensitivity—Epirubicin—ovarian cancer	0.000208	0.000516	CcSEcCtD
Vardenafil—Abdominal pain—Doxorubicin—ovarian cancer	0.000207	0.000513	CcSEcCtD
Vardenafil—Asthenia—Epirubicin—ovarian cancer	0.000203	0.000503	CcSEcCtD
Vardenafil—Pruritus—Epirubicin—ovarian cancer	0.0002	0.000496	CcSEcCtD
Vardenafil—Diarrhoea—Epirubicin—ovarian cancer	0.000193	0.00048	CcSEcCtD
Vardenafil—Hypersensitivity—Doxorubicin—ovarian cancer	0.000193	0.000478	CcSEcCtD
Vardenafil—Asthenia—Doxorubicin—ovarian cancer	0.000188	0.000465	CcSEcCtD
Vardenafil—Dizziness—Epirubicin—ovarian cancer	0.000187	0.000464	CcSEcCtD
Vardenafil—Pruritus—Doxorubicin—ovarian cancer	0.000185	0.000459	CcSEcCtD
Vardenafil—Vomiting—Epirubicin—ovarian cancer	0.00018	0.000446	CcSEcCtD
Vardenafil—Diarrhoea—Doxorubicin—ovarian cancer	0.000179	0.000444	CcSEcCtD
Vardenafil—Rash—Epirubicin—ovarian cancer	0.000178	0.000442	CcSEcCtD
Vardenafil—Dermatitis—Epirubicin—ovarian cancer	0.000178	0.000442	CcSEcCtD
Vardenafil—Headache—Epirubicin—ovarian cancer	0.000177	0.000439	CcSEcCtD
Vardenafil—Dizziness—Doxorubicin—ovarian cancer	0.000173	0.000429	CcSEcCtD
Vardenafil—Nausea—Epirubicin—ovarian cancer	0.000168	0.000416	CcSEcCtD
Vardenafil—Vomiting—Doxorubicin—ovarian cancer	0.000166	0.000412	CcSEcCtD
Vardenafil—Rash—Doxorubicin—ovarian cancer	0.000165	0.000409	CcSEcCtD
Vardenafil—Dermatitis—Doxorubicin—ovarian cancer	0.000165	0.000409	CcSEcCtD
Vardenafil—Headache—Doxorubicin—ovarian cancer	0.000164	0.000406	CcSEcCtD
Vardenafil—Nausea—Doxorubicin—ovarian cancer	0.000155	0.000385	CcSEcCtD
Vardenafil—PDE10A—Signaling by GPCR—EGFR—ovarian cancer	8.31e-05	0.000563	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CD—ovarian cancer	8.23e-05	0.000557	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by NGF—AKT1—ovarian cancer	8.21e-05	0.000556	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—VEGFA—ovarian cancer	8.15e-05	0.000552	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL6ST—ovarian cancer	8.14e-05	0.000552	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PTEN—ovarian cancer	8.13e-05	0.000551	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—PIK3CA—ovarian cancer	8.09e-05	0.000548	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—NRAS—ovarian cancer	8.05e-05	0.000546	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CD—ovarian cancer	8.02e-05	0.000543	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—ERBB2—ovarian cancer	7.94e-05	0.000538	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—PIK3CA—ovarian cancer	7.94e-05	0.000538	CbGpPWpGaD
Vardenafil—PDE6G—Disease—STAT3—ovarian cancer	7.91e-05	0.000536	CbGpPWpGaD
Vardenafil—PDE6G—Disease—NRAS—ovarian cancer	7.89e-05	0.000535	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—KRAS—ovarian cancer	7.85e-05	0.000532	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MTOR—ovarian cancer	7.84e-05	0.000531	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CB—ovarian cancer	7.84e-05	0.000531	CbGpPWpGaD
Vardenafil—PDE1B—Disease—TERT—ovarian cancer	7.83e-05	0.000531	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CG—ovarian cancer	7.82e-05	0.00053	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—TLR4—ovarian cancer	7.76e-05	0.000526	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—MAPK3—ovarian cancer	7.71e-05	0.000523	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CD—ovarian cancer	7.57e-05	0.000513	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MAPK3—ovarian cancer	7.56e-05	0.000512	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CXCL8—ovarian cancer	7.53e-05	0.00051	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—HRAS—ovarian cancer	7.48e-05	0.000507	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPP1CC—ovarian cancer	7.45e-05	0.000504	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—BRIP1—ovarian cancer	7.45e-05	0.000504	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL6ST—ovarian cancer	7.44e-05	0.000504	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CDKN1B—ovarian cancer	7.36e-05	0.000498	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MYC—ovarian cancer	7.35e-05	0.000498	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—MAPK1—ovarian cancer	7.34e-05	0.000497	CbGpPWpGaD
Vardenafil—PDE11A—GPCR downstream signaling—AKT1—ovarian cancer	7.28e-05	0.000493	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—ERBB2—ovarian cancer	7.27e-05	0.000492	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—NRAS—ovarian cancer	7.25e-05	0.000491	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CAV1—ovarian cancer	7.25e-05	0.000491	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—PIK3CA—ovarian cancer	7.21e-05	0.000489	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CASP3—ovarian cancer	7.21e-05	0.000489	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL2—ovarian cancer	7.2e-05	0.000488	CbGpPWpGaD
Vardenafil—PDE6G—Disease—MAPK1—ovarian cancer	7.19e-05	0.000487	CbGpPWpGaD
Vardenafil—PDE6G—Disease—EGFR—ovarian cancer	7.19e-05	0.000487	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CB—ovarian cancer	7.17e-05	0.000486	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MTOR—ovarian cancer	7.17e-05	0.000486	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—IL6—ovarian cancer	7.16e-05	0.000485	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—ERBB2—ovarian cancer	7.08e-05	0.00048	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CCND1—ovarian cancer	7.02e-05	0.000476	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CB—ovarian cancer	6.99e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MTOR—ovarian cancer	6.99e-05	0.000473	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—CTNNB1—ovarian cancer	6.95e-05	0.000471	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—MAPK3—ovarian cancer	6.94e-05	0.00047	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—KRAS—ovarian cancer	6.93e-05	0.00047	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PPP2R1A—ovarian cancer	6.91e-05	0.000468	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CXCL8—ovarian cancer	6.89e-05	0.000467	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CD—ovarian cancer	6.88e-05	0.000466	CbGpPWpGaD
Vardenafil—PDE1B—Disease—IL6ST—ovarian cancer	6.87e-05	0.000465	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MMP9—ovarian cancer	6.81e-05	0.000462	CbGpPWpGaD
Vardenafil—PDE6G—Disease—KRAS—ovarian cancer	6.79e-05	0.00046	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PTEN—ovarian cancer	6.77e-05	0.000459	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CDKN1B—ovarian cancer	6.73e-05	0.000456	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CXCL8—ovarian cancer	6.71e-05	0.000455	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—HRAS—ovarian cancer	6.67e-05	0.000452	CbGpPWpGaD
Vardenafil—PDE11A—Signaling by GPCR—AKT1—ovarian cancer	6.61e-05	0.000448	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—MAPK1—ovarian cancer	6.61e-05	0.000448	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—EGFR—ovarian cancer	6.61e-05	0.000448	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CB—ovarian cancer	6.6e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE1B—Disease—APC—ovarian cancer	6.6e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CASP3—ovarian cancer	6.6e-05	0.000447	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL2—ovarian cancer	6.59e-05	0.000446	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDH1—ovarian cancer	6.58e-05	0.000446	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CDKN1B—ovarian cancer	6.56e-05	0.000444	CbGpPWpGaD
Vardenafil—PDE10A—GPCR downstream signaling—AKT1—ovarian cancer	6.49e-05	0.000439	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CASP3—ovarian cancer	6.43e-05	0.000435	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CCND1—ovarian cancer	6.42e-05	0.000435	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL2—ovarian cancer	6.42e-05	0.000435	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—IL6—ovarian cancer	6.39e-05	0.000433	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—PIK3CA—ovarian cancer	6.37e-05	0.000431	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—CTNNB1—ovarian cancer	6.36e-05	0.000431	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—CXCL8—ovarian cancer	6.34e-05	0.00043	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CD—ovarian cancer	6.28e-05	0.000426	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CCND1—ovarian cancer	6.26e-05	0.000424	CbGpPWpGaD
Vardenafil—PDE6G—Disease—PIK3CA—ovarian cancer	6.24e-05	0.000423	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—KRAS—ovarian cancer	6.24e-05	0.000423	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MMP9—ovarian cancer	6.23e-05	0.000422	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PTEN—ovarian cancer	6.2e-05	0.00042	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—CTNNB1—ovarian cancer	6.2e-05	0.00042	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—TP53—ovarian cancer	6.16e-05	0.000417	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—NME2—ovarian cancer	6.15e-05	0.000416	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—VEGFA—ovarian cancer	6.12e-05	0.000415	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MMP9—ovarian cancer	6.07e-05	0.000411	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—IL2—ovarian cancer	6.06e-05	0.000411	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—STAT3—ovarian cancer	6.06e-05	0.00041	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—NRAS—ovarian cancer	6.04e-05	0.000409	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PTEN—ovarian cancer	6.04e-05	0.000409	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CB—ovarian cancer	5.99e-05	0.000406	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—HRAS—ovarian cancer	5.89e-05	0.000399	CbGpPWpGaD
Vardenafil—PDE10A—Signaling by GPCR—AKT1—ovarian cancer	5.89e-05	0.000399	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CD—ovarian cancer	5.8e-05	0.000393	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MAPK3—ovarian cancer	5.79e-05	0.000392	CbGpPWpGaD
Vardenafil—PDE6G—Disease—HRAS—ovarian cancer	5.78e-05	0.000391	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—CXCL8—ovarian cancer	5.76e-05	0.00039	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—PIK3CA—ovarian cancer	5.73e-05	0.000388	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MYC—ovarian cancer	5.63e-05	0.000381	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—VEGFA—ovarian cancer	5.6e-05	0.000379	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—ERBB2—ovarian cancer	5.55e-05	0.000376	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—STAT3—ovarian cancer	5.54e-05	0.000375	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—NRAS—ovarian cancer	5.53e-05	0.000375	CbGpPWpGaD
Vardenafil—PDE6G—Disease—IL6—ovarian cancer	5.53e-05	0.000374	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—MAPK1—ovarian cancer	5.51e-05	0.000373	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—EGFR—ovarian cancer	5.51e-05	0.000373	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL2—ovarian cancer	5.51e-05	0.000373	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TERT—ovarian cancer	5.49e-05	0.000372	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MTOR—ovarian cancer	5.48e-05	0.000371	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CB—ovarian cancer	5.48e-05	0.000371	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—VEGFA—ovarian cancer	5.45e-05	0.000369	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—STAT3—ovarian cancer	5.4e-05	0.000366	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—NRAS—ovarian cancer	5.39e-05	0.000365	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—HRAS—ovarian cancer	5.3e-05	0.000359	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MAPK3—ovarian cancer	5.29e-05	0.000359	CbGpPWpGaD
Vardenafil—PDE1B—Hemostasis—AKT1—ovarian cancer	5.2e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—KRAS—ovarian cancer	5.2e-05	0.000352	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MAPK3—ovarian cancer	5.16e-05	0.00035	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MYC—ovarian cancer	5.15e-05	0.000349	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CDKN1B—ovarian cancer	5.14e-05	0.000348	CbGpPWpGaD
Vardenafil—PDE1B—Disease—ERBB2—ovarian cancer	5.12e-05	0.000347	CbGpPWpGaD
Vardenafil—PDE6G—Disease—AKT1—ovarian cancer	5.1e-05	0.000345	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—IL6—ovarian cancer	5.08e-05	0.000344	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CAV1—ovarian cancer	5.07e-05	0.000344	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MTOR—ovarian cancer	5.06e-05	0.000343	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CB—ovarian cancer	5.06e-05	0.000343	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—MAPK1—ovarian cancer	5.04e-05	0.000341	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—EGFR—ovarian cancer	5.04e-05	0.000341	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL2—ovarian cancer	5.03e-05	0.000341	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MYC—ovarian cancer	5.02e-05	0.00034	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—YAP1—ovarian cancer	4.99e-05	0.000338	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—MAPK1—ovarian cancer	4.91e-05	0.000333	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—EGFR—ovarian cancer	4.91e-05	0.000333	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ESR1—ovarian cancer	4.89e-05	0.000331	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—CTNNB1—ovarian cancer	4.86e-05	0.000329	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL6ST—ovarian cancer	4.81e-05	0.000326	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—PIK3CA—ovarian cancer	4.78e-05	0.000324	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—KRAS—ovarian cancer	4.76e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CDKN1B—ovarian cancer	4.75e-05	0.000322	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PTEN—ovarian cancer	4.73e-05	0.000321	CbGpPWpGaD
Vardenafil—PDE1B—Innate Immune System—AKT1—ovarian cancer	4.68e-05	0.000317	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—KRAS—ovarian cancer	4.64e-05	0.000314	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—TP53—ovarian cancer	4.62e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—APC—ovarian cancer	4.62e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CG—ovarian cancer	4.62e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—NRAS—ovarian cancer	4.62e-05	0.000313	CbGpPWpGaD
Vardenafil—PDE1B—Disease—CTNNB1—ovarian cancer	4.48e-05	0.000304	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—MAPK3—ovarian cancer	4.43e-05	0.0003	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—HRAS—ovarian cancer	4.42e-05	0.0003	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—PIK3CA—ovarian cancer	4.37e-05	0.000296	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PTEN—ovarian cancer	4.37e-05	0.000296	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—PIK3CA—ovarian cancer	4.26e-05	0.000289	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—STAT3—ovarian cancer	4.23e-05	0.000287	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—IL6—ovarian cancer	4.23e-05	0.000287	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—TP53—ovarian cancer	4.23e-05	0.000286	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—NRAS—ovarian cancer	4.22e-05	0.000286	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—MAPK1—ovarian cancer	4.21e-05	0.000285	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—EGFR—ovarian cancer	4.21e-05	0.000285	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—TP53—ovarian cancer	4.12e-05	0.000279	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—FASN—ovarian cancer	4.07e-05	0.000276	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CD—ovarian cancer	4.06e-05	0.000275	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MAPK3—ovarian cancer	4.04e-05	0.000274	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—HRAS—ovarian cancer	4.04e-05	0.000274	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—PIK3CA—ovarian cancer	4.02e-05	0.000273	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC5A5—ovarian cancer	4e-05	0.000271	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—KRAS—ovarian cancer	3.98e-05	0.000269	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYTB—ovarian cancer	3.96e-05	0.000268	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—HRAS—ovarian cancer	3.94e-05	0.000267	CbGpPWpGaD
Vardenafil—PDE1B—Disease—STAT3—ovarian cancer	3.91e-05	0.000265	CbGpPWpGaD
Vardenafil—PDE11A—Signaling Pathways—AKT1—ovarian cancer	3.9e-05	0.000265	CbGpPWpGaD
Vardenafil—PDE1B—Disease—NRAS—ovarian cancer	3.9e-05	0.000264	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—IL6—ovarian cancer	3.87e-05	0.000262	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—SLC2A1—ovarian cancer	3.87e-05	0.000262	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—MAPK1—ovarian cancer	3.85e-05	0.000261	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—EGFR—ovarian cancer	3.85e-05	0.000261	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—IL6—ovarian cancer	3.77e-05	0.000256	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MAPK3—ovarian cancer	3.73e-05	0.000253	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CYP1B1—ovarian cancer	3.71e-05	0.000251	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—PIK3CA—ovarian cancer	3.65e-05	0.000248	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—KRAS—ovarian cancer	3.63e-05	0.000246	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MYC—ovarian cancer	3.63e-05	0.000246	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—ERBB2—ovarian cancer	3.59e-05	0.000243	CbGpPWpGaD
Vardenafil—PDE6G—Signaling Pathways—AKT1—ovarian cancer	3.57e-05	0.000242	CbGpPWpGaD
Vardenafil—PDE1B—Disease—MAPK1—ovarian cancer	3.55e-05	0.000241	CbGpPWpGaD
Vardenafil—PDE1B—Disease—EGFR—ovarian cancer	3.55e-05	0.000241	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MTOR—ovarian cancer	3.54e-05	0.00024	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CB—ovarian cancer	3.54e-05	0.00024	CbGpPWpGaD
Vardenafil—PDE10A—Signaling Pathways—AKT1—ovarian cancer	3.48e-05	0.000236	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPP1CC—ovarian cancer	3.46e-05	0.000235	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—BRIP1—ovarian cancer	3.46e-05	0.000235	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CXCL8—ovarian cancer	3.4e-05	0.000231	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—HRAS—ovarian cancer	3.38e-05	0.000229	CbGpPWpGaD
Vardenafil—PDE1B—Disease—KRAS—ovarian cancer	3.36e-05	0.000227	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—PIK3CA—ovarian cancer	3.34e-05	0.000226	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CDKN1B—ovarian cancer	3.32e-05	0.000225	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PPP2R1A—ovarian cancer	3.29e-05	0.000223	CbGpPWpGaD
Vardenafil—PDE1B—GPCR downstream signaling—AKT1—ovarian cancer	3.29e-05	0.000223	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CASP3—ovarian cancer	3.26e-05	0.000221	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL2—ovarian cancer	3.25e-05	0.00022	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—IL6—ovarian cancer	3.24e-05	0.000219	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CCND1—ovarian cancer	3.17e-05	0.000215	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—CTNNB1—ovarian cancer	3.14e-05	0.000213	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—HRAS—ovarian cancer	3.09e-05	0.000209	CbGpPWpGaD
Vardenafil—PDE1B—Disease—PIK3CA—ovarian cancer	3.08e-05	0.000209	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MMP9—ovarian cancer	3.08e-05	0.000209	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PTEN—ovarian cancer	3.06e-05	0.000207	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—ABCB1—ovarian cancer	3.05e-05	0.000207	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—TYMS—ovarian cancer	3e-05	0.000203	CbGpPWpGaD
Vardenafil—PDE1B—Signaling by GPCR—AKT1—ovarian cancer	2.99e-05	0.000202	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—IL6—ovarian cancer	2.96e-05	0.0002	CbGpPWpGaD
Vardenafil—PDE1B—Disease—HRAS—ovarian cancer	2.85e-05	0.000193	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—VEGFA—ovarian cancer	2.76e-05	0.000187	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—STAT3—ovarian cancer	2.74e-05	0.000185	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—NRAS—ovarian cancer	2.73e-05	0.000185	CbGpPWpGaD
Vardenafil—PDE1B—Disease—IL6—ovarian cancer	2.73e-05	0.000185	CbGpPWpGaD
Vardenafil—PDE1B—Immune System—AKT1—ovarian cancer	2.73e-05	0.000185	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAPK3—ovarian cancer	2.61e-05	0.000177	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MYC—ovarian cancer	2.54e-05	0.000172	CbGpPWpGaD
Vardenafil—PDE1B—Disease—AKT1—ovarian cancer	2.52e-05	0.000171	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—MAPK1—ovarian cancer	2.49e-05	0.000169	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—EGFR—ovarian cancer	2.49e-05	0.000169	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—CAV1—ovarian cancer	2.42e-05	0.000164	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—KRAS—ovarian cancer	2.35e-05	0.000159	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—YAP1—ovarian cancer	2.32e-05	0.000157	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CG—ovarian cancer	2.2e-05	0.000149	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—PIK3CA—ovarian cancer	2.16e-05	0.000146	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—TP53—ovarian cancer	2.09e-05	0.000141	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—HRAS—ovarian cancer	2e-05	0.000135	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CD—ovarian cancer	1.93e-05	0.000131	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—IL6—ovarian cancer	1.91e-05	0.00013	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—FASN—ovarian cancer	1.89e-05	0.000128	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC5A5—ovarian cancer	1.86e-05	0.000126	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—SLC2A1—ovarian cancer	1.8e-05	0.000122	CbGpPWpGaD
Vardenafil—PDE1B—Signaling Pathways—AKT1—ovarian cancer	1.76e-05	0.000119	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CYP1B1—ovarian cancer	1.72e-05	0.000117	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CB—ovarian cancer	1.69e-05	0.000114	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.53e-05	0.000104	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PTEN—ovarian cancer	1.46e-05	9.87e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.42e-05	9.62e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—TYMS—ovarian cancer	1.39e-05	9.45e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—CAV1—ovarian cancer	1.12e-05	7.61e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.03e-05	6.97e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.02e-05	6.93e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CD—ovarian cancer	9e-06	6.09e-05	CbGpPWpGaD
Vardenafil—CYP3A5—Metabolism—AKT1—ovarian cancer	8.4e-06	5.69e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CB—ovarian cancer	7.84e-06	5.31e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PTEN—ovarian cancer	6.78e-06	4.59e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—PIK3CA—ovarian cancer	4.78e-06	3.24e-05	CbGpPWpGaD
Vardenafil—CYP3A4—Metabolism—AKT1—ovarian cancer	3.9e-06	2.65e-05	CbGpPWpGaD
